News and Events => Political and Legal News => Topic started by: Jessica_Rose on June 22, 2026, 10:23:46 AM Return to Full Version
Title: NHS Pathways puberty blockers trial sets minimum ages for trans youngsters
Post by: Jessica_Rose on June 22, 2026, 10:23:46 AM
Post by: Jessica_Rose on June 22, 2026, 10:23:46 AM
NHS Pathways puberty blockers trial sets minimum ages for trans youngsters
https://www.thepinknews.com/2026/06/22/nhs-puberty-blockers-pathways-trial-ages-2026/
Jack Wetherill (22 June 2026)
NHS England's Pathways Trial for puberty blockers has introduced minimum entry ages of 11 for trans boys and 12 for trans girls, alongside revised safeguards ahead of its planned start date.
The changes were set out in an update on the Pathways clinical trial published on 19 June.
Young people taking part will undergo more than 13 hours of medical assessments and complete around 50 forms before accessing treatment, alongside physical examinations. Half of participants will receive puberty blockers immediately, while others will wait one year.
Children must have parental consent and must meet eligibility requirements to take part, including "demonstrating a good understanding of the intervention and its possible benefits and risks".
The £10million, two-year study was launched late last year, but was put on pause by officials in February of this year over concerns for safety and welfare. It is scheduled to commence on 1 August 2026 under the updated guidance.
The Medicines and Healthcare products Regulatory Agency (MHRA) said: "The modified protocol includes strengthened safeguards including the introduction of minimum ages of entry to the trial and more clearly defined discontinuation measures."
https://www.thepinknews.com/2026/06/22/nhs-puberty-blockers-pathways-trial-ages-2026/
Jack Wetherill (22 June 2026)
NHS England's Pathways Trial for puberty blockers has introduced minimum entry ages of 11 for trans boys and 12 for trans girls, alongside revised safeguards ahead of its planned start date.
The changes were set out in an update on the Pathways clinical trial published on 19 June.
Young people taking part will undergo more than 13 hours of medical assessments and complete around 50 forms before accessing treatment, alongside physical examinations. Half of participants will receive puberty blockers immediately, while others will wait one year.
Children must have parental consent and must meet eligibility requirements to take part, including "demonstrating a good understanding of the intervention and its possible benefits and risks".
The £10million, two-year study was launched late last year, but was put on pause by officials in February of this year over concerns for safety and welfare. It is scheduled to commence on 1 August 2026 under the updated guidance.
The Medicines and Healthcare products Regulatory Agency (MHRA) said: "The modified protocol includes strengthened safeguards including the introduction of minimum ages of entry to the trial and more clearly defined discontinuation measures."